{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015390","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.588675+00:00","generated_at":"2026-06-11T01:15:10.243963+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adaptimmune receives Nasdaq deficiency notice for ADS bid price below $1.00; 180-day cure period ends Feb 27, 2024","bullets":["Received Nasdaq notice on Aug 31, 2023 for non-compliance with minimum bid price of $1.00 per ADS for 30 consecutive business days.","Has 180 calendar days, until February 27, 2024, to regain compliance by closing at $1.00 for ten consecutive business days.","If not compliant by Feb 27, may transfer to Nasdaq Capital Market for additional 180-day period subject to other standards.","Company intends to monitor bid price and assess actions; no immediate effect on listing or trading."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015390","json":"https://secwatch.observer/filing/0001558370-23-015390.json","markdown":"https://secwatch.observer/filing/0001558370-23-015390.md","text":"https://secwatch.observer/filing/0001558370-23-015390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000155837023015390/0001558370-23-015390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000155837023015390/adap-20230831x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:15:10.243963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"603f3c9461dc13030d40ab073b326e9631a79bfc","claim":"Adaptimmune Therapeutics PLC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"August 31, 2023, Adaptimmune Therapeutics plc (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), because the minimum bid price of the Company’s American Depositary Shares (“ADSs”) has been below $1.00 per share for 30 consecutive business days (the “Notice”). The Notice has no immediate effect on the listing or trading of the Company’s ADSs on The Nasdaq Global Select Market. ​ In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until February 27, 2024, to","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000155837023015390/0001558370-23-015390-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}